Paper38540800
Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors.
Sobral D and 17 others. Biomolecules, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors. Papers, record 38540800. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38540800
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Spondylitis, Ankylosing | Major topic |
| Antirheumatic Agents | Major topic |
| Axial Spondyloarthritis | Major topic |
| Humans | |
| Tumor Necrosis Factor Inhibitors | |
| Adalimumab | |
| Tumor Necrosis Factor-alpha | |
| Treatment Outcome |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31531695 | [Current treatment of axial spondylarthritis : Clinical efficacy]. | Z Rheumatol | 2020 | https://conductscience.org/library/papers/31531695 | PubMed |
| 2 | 20473175 | New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. | Curr Opin Rheumatol | 2010 | https://conductscience.org/library/papers/20473175 | PubMed |
| 3 | 15956838 | Management and treatment of ankylosing spondylitis. | Curr Opin Rheumatol | 2005 | https://conductscience.org/library/papers/15956838 | PubMed |
| 4 | 15044211 | Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. | Ann Rheum Dis | 2004 | https://conductscience.org/library/papers/15044211 | PubMed |
| 5 | 11508441 | Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. | Arthritis Rheum | 2001 | https://conductscience.org/library/papers/11508441 | PubMed |
| 6 | 15037444 | Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. | Ann Rheum Dis | 2004 | https://conductscience.org/library/papers/15037444 | PubMed |
| 7 | 15113999 | Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. | Rheumatology (Oxford) | 2004 | https://conductscience.org/library/papers/15113999 | PubMed |
| 8 | 31518426 | The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. | Rheumatology (Oxford) | 2019 | https://conductscience.org/library/papers/31518426 | PubMed |
| 9 | 29344893 | Profiling Tumor Infiltrating Immune Cells with CIBERSORT. | Methods Mol Biol | 2018 | https://conductscience.org/library/papers/29344893 | PubMed |
| 10 | 25167369 | The window of opportunity: a relevant concept for axial spondyloarthritis. | Arthritis Res Ther | 2014 | https://conductscience.org/library/papers/25167369 | PubMed |
| 11 | 17047224 | Regulation and function of IKK and IKK-related kinases. | Sci STKE | 2006 | https://conductscience.org/library/papers/17047224 | PubMed |
| 12 | 31565244 | Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. | RMD Open | 2019 | https://conductscience.org/library/papers/31565244 | PubMed |
| 13 | 24718959 | Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. | Ann Rheum Dis | 2015 | https://conductscience.org/library/papers/24718959 | PubMed |
| 14 | 20032971 | CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20032971 | PubMed |
| 15 | 20062062 | Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. | Nat Genet | 2010 | https://conductscience.org/library/papers/20062062 | PubMed |
| 16 | 31647025 | Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. | Arthritis Res Ther | 2019 | https://conductscience.org/library/papers/31647025 | PubMed |
| 17 | 17690207 | Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. | J Mol Diagn | 2007 | https://conductscience.org/library/papers/17690207 | PubMed |
| 18 | 27043002 | Near-optimal probabilistic RNA-seq quantification. | Nat Biotechnol | 2016 | https://conductscience.org/library/papers/27043002 | PubMed |
| 19 | 18006539 | MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. | Ann Rheum Dis | 2008 | https://conductscience.org/library/papers/18006539 | PubMed |
| 20 | 28894079 | Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. | Acta Reumatol Port | 2017 | https://conductscience.org/library/papers/28894079 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41427121 | From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis. | Ther Adv Musculoskelet Dis | 2025 | https://conductscience.org/library/papers/41427121 |
Source PubMed
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFF3 | 3899 | PubTator's text mining | https://conductscience.org/library/genes/3899 | NCBI Gene |
| APOA1 | 335 | PubTator's text mining | https://conductscience.org/library/genes/335 | NCBI Gene |
| APOA2 | 336 | PubTator's text mining | https://conductscience.org/library/genes/336 | NCBI Gene |
| APOD | 347 | PubTator's text mining | https://conductscience.org/library/genes/347 | NCBI Gene |
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| HP | 3240 | PubTator's text mining | https://conductscience.org/library/genes/3240 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38540800
GET https://conductscience.org/api/papers/v1/38540800/references?page=2